Atrial fibrillation
Conditions
Interventions
None listed
Sponsors
Amsterdam UMC
Eligibility
Inclusion criteria
Inclusion criteria: - Elective cardioversion is planned - Adequate anticoagulation with vitamin K antagonists or NOACs for at least 3 weeks prior to the procedure - Beta-blocker use at baseline, at least continued up to the second 123I-mIBG scintigraphy - Age between 18 and 80 years - Legally competent and willing and able to sign informed consent - Willing and able to conform to the study protocol
Exclusion criteria
Exclusion criteria: - Unable or unwilling to comply with study procedures - Discontinuing of beta-blockers during follow-up period up to the second 123I-mIBG scintigraphy - Discontinuing or switch of antiarrhythmic drugs during follow-up period up to the second 123I-mIBG scintigraphyArrhythmia other than AF as the indication for cardioversion - Emergency electrical cardioversion - Overt heart failure symptoms (i.e. oedema, pulmonary rales, orthopnoea), NYHA class=2 and/or left ventricular ejection fraction 50% stenosis) - Myocardial infarction or acute coronary syndrome within 3 months prior to the cardioversion - History of catheter or surgical ablation for any arrhythmia - A history of a thoracotomy - CVA within 6 months prior to the cardioversion - Active malignant disease - History of neurosecretory tumours - Pregnancy or of childbearing potential without adequate contraception - History of previous radiation therapy of the thorax - Circumstances that prevent follow-up (no permanent home or address, transient, etc.) - Life expectancy <2 years.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Documented recurrence of AF (or other atrial arrhythmias lasting longer than 30 seconds as per HRS/EHRA/ECAS consensus document definition) within the first 12 months after cardioversion. Documentation of recurrent AF includes, but is not limited to: a)ECG documentation of AF recurrence b)Read out of pacemaker or ICD demonstrating AF c)Holter recordings demonstrating AF d)Subsequent electrical or chemical cardioversion for any supraventricular arrhythmia | — |
Secondary
| Measure | Time frame |
|---|---|
| a) AF recurrence within the first year after cardioversion (documented as stated above) b) Hospitalisation for atrial arrhythmias c) Hospitalisation for heart failure | — |
Contacts
Public ContactJoris R. de Groot
Amsterdam UMC - Locatie AMC
Outcome results
None listed